- Home
- UTHR vs DECK Comparison
UTHR vs DECK Comparison
Compare UTHR & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- DECK
- Stock Information
- Founded
- UTHR 1996
- DECK 1973
- Country
- UTHR United States
- DECK United States
- Employees
- UTHR N/A
- DECK N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- DECK Shoe Manufacturing
- Sector
- UTHR Health Care
- DECK Consumer Discretionary
- Exchange
- UTHR Nasdaq
- DECK Nasdaq
- Market Cap
- UTHR 14.4B
- DECK 15.2B
- IPO Year
- UTHR 1999
- DECK 1993
- Fundamental
- Price
- UTHR $297.02
- DECK $101.80
- Analyst Decision
- UTHR Buy
- DECK Buy
- Analyst Count
- UTHR 13
- DECK 22
- Target Price
- UTHR $383.08
- DECK $144.56
- AVG Volume (30 Days)
- UTHR 551.5K
- DECK 2.8M
- Earning Date
- UTHR 07-30-2025
- DECK 07-24-2025
- Dividend Yield
- UTHR N/A
- DECK N/A
- EPS Growth
- UTHR 18.86
- DECK 30.25
- EPS
- UTHR 25.10
- DECK 6.33
- Revenue
- UTHR $2,994,100,000.00
- DECK $4,985,612,000.00
- Revenue This Year
- UTHR $14.30
- DECK $10.38
- Revenue Next Year
- UTHR $6.32
- DECK $7.85
- P/E Ratio
- UTHR $11.79
- DECK $16.07
- Revenue Growth
- UTHR 19.84
- DECK 16.27
- 52 Week Low
- UTHR $266.98
- DECK $93.72
- 52 Week High
- UTHR $417.82
- DECK $223.98
- Technical
- Relative Strength Index (RSI)
- UTHR 51.32
- DECK 40.61
- Support Level
- UTHR $286.68
- DECK $104.05
- Resistance Level
- UTHR $301.75
- DECK $106.86
- Average True Range (ATR)
- UTHR 6.73
- DECK 2.84
- MACD
- UTHR 1.81
- DECK 0.45
- Stochastic Oscillator
- UTHR 77.16
- DECK 38.06
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.